What Happens at the Neuromuscular Junction?

The neuromuscular junction (NMJ) is the specialized communication site between a motor nerve terminal and a skeletal muscle fiber.

Under normal conditions, an electrical impulse known as an action potential travels along the motor neuron and reaches the presynaptic nerve terminal. This triggers calcium-dependent fusion of acetylcholine-containing synaptic vesicles with the presynaptic membrane.

Acetylcholine is then released into the synaptic cleft, crosses the small space between nerve and muscle, and binds to nicotinic acetylcholine receptors on the muscle membrane.

This produces depolarization of the muscle membrane and initiates the sequence leading to muscle contraction. [1–3]

Botulinum toxin type A (BoNT-A) modifies this communication primarily on the presynaptic side of the neuromuscular junction by interfering with neurotransmitter release. [1–4]

The BoNT-A Mechanism Can Be Divided Into Several Key Steps

At the molecular level, BoNT-A does not simply “relax the muscle.”

Its effect results from a sequence of events involving:

1. neuronal binding
2. receptor-mediated internalization
3. translocation of the light chain
4. SNAP-25 cleavage
5. inhibition of synaptic-vesicle fusion
6. reduced acetylcholine release
7. temporary reduction in muscle activation [1–5]

Understanding these steps helps explain both the therapeutic action and the temporary nature of BoNT-A treatment.

Step 1: BoNT-A Recognizes the Presynaptic Nerve Terminal

BoNT/A is composed functionally of a heavy chain and a light chain connected by a disulfide bond. The domains of the heavy chain are involved in neuronal binding and translocation, whereas the light chain contains the proteolytic activity responsible for cleavage of the intracellular target. [3]

Neuronal binding involves interactions with membrane components including polysialogangliosides and a protein receptor.

A major advance in understanding BoNT/A occurred when Dong and colleagues identified synaptic vesicle protein 2 (SV2) as a protein receptor for BoNT/A. Experimental evidence showed that reduced SV2 expression inhibited toxin entry, whereas expression of SV2 isoforms restored susceptibility. [2]

SV2 exists in several isoforms—SV2A, SV2B and SV2C—and is associated with synaptic vesicles. [2,3]

This receptor interaction contributes to the preferential entry of BoNT/A into nerve terminals.

Step 2: The Toxin Is Internalized Into the Nerve Terminal

Following receptor binding, BoNT/A is taken into the presynaptic nerve terminal through receptor-mediated endocytosis. [2–5]

The toxin therefore does not remain only on the outside of the neuron. It enters a vesicular compartment within the nerve terminal.

Acidification of this compartment is an important next step because the change in pH facilitates conformational changes required for translocation of the toxin's light chain across the vesicle membrane. [3,5]

Step 3: The Light Chain Reaches the Neuronal Cytosol

The heavy-chain translocation domain helps deliver the light chain across the vesicular membrane into the neuronal cytosol. [3,5]

Once in the cytosol, the light chain functions as a zinc-dependent endopeptidase.

This enzymatic activity is central to the characteristic action of BoNT/A. [1,3,5]

Step 4: BoNT-A Cleaves SNAP-25

The major intracellular substrate of BoNT/A is SNAP-25, or synaptosomal-associated protein of 25 kDa.

The classic study by Blasi and colleagues demonstrated that BoNT/A selectively proteolyzes SNAP-25 and established that the BoNT/A light chain acts as a zinc-dependent protease. [1]

Subsequent molecular work showed that BoNT/A cleaves SNAP-25 at the peptide bond between Gln197 and Arg198. [6]

This apparently small molecular event has major functional consequences because SNAP-25 is a critical component of the machinery required for neurotransmitter-containing vesicles to fuse with the presynaptic membrane.

What Is the SNARE Complex?

SNAP-25 does not work alone.

It is part of the SNARE protein machinery, which includes proteins such as SNAP-25, syntaxin and synaptobrevin/VAMP. These proteins cooperate in docking and fusion of synaptic vesicles with the neuronal membrane. [1,4]

A useful way to understand this is to think of the SNARE system as part of the molecular machinery that allows a vesicle containing neurotransmitter to attach to and merge with the nerve-terminal membrane.

Without successful membrane fusion, the neurotransmitter inside the vesicle cannot be efficiently released into the synaptic cleft.

By cleaving SNAP-25, BoNT/A disrupts this exocytotic machinery. [1,3,4]

Step 5: Acetylcholine Release Is Reduced

At the neuromuscular junction, one of the key consequences is inhibition of acetylcholine release.

Because fewer acetylcholine-containing vesicles can successfully complete exocytosis, the amount of neurotransmitter available to activate the postsynaptic muscle membrane decreases. [1,3,4]

This reduces effective neuromuscular transmission.

The targeted muscle consequently receives less neural stimulation and its contractile activity is reduced.

Clinically, this is commonly described as temporary chemodenervation.

Does BoNT-A Directly Act on the Muscle Fiber?

The primary established mechanism at the neuromuscular junction is presynaptic.

BoNT-A interferes with neurotransmitter release from the nerve terminal rather than acting as a conventional direct skeletal-muscle relaxant.

This distinction is important.

The muscle contracts less because neural transmission to the muscle has been reduced—not because the toxin simply “softens” or directly switches off the muscle fiber itself. [1–5]

Is Acetylcholine the Only Neurotransmitter BoNT-A Can Affect?

At the neuromuscular junction, acetylcholine is the clinically important neurotransmitter for motor transmission.

However, the molecular machinery targeted by botulinum neurotoxins is involved in vesicular neurotransmitter release more broadly. Mechanistic literature therefore indicates that BoNT effects should not be described as intrinsically limited to acetylcholine-containing terminals in every biological context. [3,7]

For a neuromuscular-junction article, however, the most clinically relevant sequence remains:

BoNT-A → SNAP-25 cleavage → reduced acetylcholine release → reduced skeletal-muscle activation.

Why Doesn't the Effect Begin the Instant the Injection Is Given?

The molecular mechanism requires several biological steps.

BoNT/A must reach an appropriate nerve terminal, bind to its neuronal receptors, undergo internalization and translocation, and exert enzymatic activity on SNAP-25 before neurotransmitter release becomes sufficiently impaired to produce a clinically measurable effect. [2,3,5]

For this reason, injection and visible clinical effect are not the same event.

The exact clinical onset should be taken from product- and indication-specific studies rather than inferred solely from the molecular mechanism.

Why Is the Effect Temporary Rather Than Permanent?

BoNT-A does not normally produce permanent destruction of the neuromuscular junction when used therapeutically.

Functional transmission gradually recovers as the nerve terminal restores its ability to release neurotransmitter. Reviews of the mechanism describe recovery as involving restoration of functional synaptic transmission; transient nerve-terminal sprouting has also been observed experimentally during the recovery process. [3,7]

The biology of recovery is therefore more complex than simply saying that the drug “leaves the muscle.”

The duration of clinical effect also cannot be predicted from mechanism alone. It varies according to the toxin preparation, dose, muscle, indication, treatment protocol, endpoint and individual patient factors. [3]

Why Does Injection Location Matter?

BoNT-A requires access to susceptible nerve terminals in the treated region.

The clinical effect therefore depends not only on the molecular mechanism but also on dose, injection location, anatomy and technique.

A highly effective molecular mechanism does not eliminate the importance of accurate treatment planning.

The target muscle must be identified correctly, and the injection strategy should reflect the anatomy and clinical objective.

This explains why knowledge of the mechanism alone cannot predict the result of a treatment.

Does the Mechanism Tell Us How Much Toxin to Use?

No.

Knowing that BoNT-A cleaves SNAP-25 explains how the toxin can reduce neurotransmission. It does not by itself establish the appropriate clinical dose.

Dose selection must be based on product-specific labeling and/or relevant clinical evidence.

Molecular mechanism cannot be used to derive a universal dosing formula.

Does Sharing the Same Mechanism Mean BoNT-A Products Are Equivalent?

No.

Different BoNT-A products can share the fundamental mechanism of neuronal uptake, SNAP-25 cleavage and inhibition of neurotransmitter release while still differing in manufacturing, formulation, potency assay, labeled units, approved indications and product-specific clinical evidence. [8,9]

Therefore:

same molecular target ≠ same product

and

same molecular mechanism ≠ automatic clinical interchangeability

This distinction is particularly important when interpreting units or attempting to compare doses between brands.

Where Does Neuronox Fit Into This Mechanism?

Neuronox is a Botulinum Toxin Type A product manufactured by Medytox Inc., Republic of Korea, according to the Thai product information used as a source for BotoxWiki. [10]

As a BoNT-A product, its therapeutic rationale is based on the characteristic type-A mechanism involving inhibition of cholinergic neurotransmission.

However, mechanism alone should not be used to make claims about a particular product's clinical efficacy.

That requires product-specific clinical studies.

Neuronox has published randomized comparative clinical evidence in several settings, including glabellar lines, essential blepharospasm, cerebral-palsy-associated spastic equinus and post-stroke upper-limb spasticity. [11–14]

This distinction is useful:

Mechanistic evidence explains why BoNT-A can work.
Product-specific clinical evidence tells us what was actually observed with Neuronox in studied patients.

Key Takeaways

At the neuromuscular junction, BoNT-A acts primarily at the presynaptic motor nerve terminal.

It binds to neuronal surface components including SV2, undergoes receptor-mediated internalization, and delivers its zinc-dependent protease light chain into the neuronal cytosol. [2,3,5]

The light chain cleaves SNAP-25, disrupting the SNARE-dependent vesicle-fusion process required for efficient neurotransmitter exocytosis. [1,3,6]

At motor nerve terminals, the resulting reduction in acetylcholine release decreases stimulation of the target muscle and temporarily reduces muscle activity.

Recovery occurs over time as functional neuromuscular transmission is restored. [3,7]

Finally, understanding this shared mechanism does not establish that all BoNT-A products are identical or interchangeable. Product-specific dosing, units, labeling and clinical evidence remain essential. [8–10]

References

1. Blasi J, Chapman ER, Link E, et al. Botulinum neurotoxin A selectively cleaves the synaptic protein SNAP-25. Nature. 1993;365(6442):160–163. doi:10.1038/365160a0.

2. Dong M, Yeh F, Tepp WH, et al. SV2 is the protein receptor for botulinum neurotoxin A. Science. 2006;312(5773):592–596. doi:10.1126/science.1123654.

3. Pirazzini M, Rossetto O, Eleopra R, Montecucco C. Botulinum neurotoxins: biology, pharmacology, and toxicology. Pharmacol Rev. 2017;69(2):200–235. doi:10.1124/pr.116.012658.

4. Meunier FA, Schiavo G, Molgó J. Botulinum neurotoxins: from paralysis to recovery of functional neuromuscular transmission. J Physiol Paris. 2002;96(1–2):105–113.

5. Dolly JO, Lawrence GW. Molecular basis for the therapeutic effectiveness of botulinum neurotoxin type A. Neurourol Urodyn. 2014;33(Suppl 3):S14–S20. doi:10.1002/nau.22634.

6. Schiavo G, Santucci A, Dasgupta BR, et al. Botulinum neurotoxins serotypes A and E cleave SNAP-25 at distinct COOH-terminal peptide bonds. FEBS Lett. 1993;335(1):99–103. doi:10.1016/0014-5793(93)80448-4.

7. Poulain B, Popoff MR. Why are botulinum neurotoxin-producing bacteria so diverse and botulinum neurotoxins so toxic? Toxins (Basel). 2019;11(1):34. doi:10.3390/toxins11010034.

8. Rosales RL, Bigalke H, Dressler D. Pharmacology of botulinum toxin: differences between type A preparations. Eur J Neurol. 2006;13(Suppl 1):2–10.

9. Brin MF, James C, Maltman J. Botulinum toxin type A products are not interchangeable: a review of the evidence. Biologics. 2014;8:227–241. doi:10.2147/BTT.S65603.

10. NEURONOX (Botulinum toxin Type A) Thai Product Information. Revised April 3, 2023. Medytox Inc., Republic of Korea.

11. Lee WS, et al. Efficacy and safety of a novel botulinum toxin type A product for the treatment of moderate to severe glabellar lines: a randomized, double-blind, active-controlled multicenter study. Dermatol Surg. 2013;39(1 Pt 2):171–178. PMID: 23301821.

12. Yoon JS, Kim JC, Lee SY. Double-blind, randomized, comparative study of Meditoxin versus Botox in the treatment of essential blepharospasm. Korean J Ophthalmol. 2009;23(3):137–141. doi:10.3341/kjo.2009.23.3.137.

13. Kim K, Shin HI, Kwon BS, et al. Neuronox versus BOTOX for spastic equinus gait in children with cerebral palsy: a randomized, double-blinded, controlled multicentre clinical trial. Dev Med Child Neurol. 2011;53(3):239–244. doi:10.1111/j.1469-8749.2010.03830.x.

14. Nam HS, et al. Efficacy and safety of Neuronox versus BOTOX for post-stroke upper limb spasticity: a multicenter randomized controlled trial. PLoS One. 2015;10:e0128633. doi:10.1371/journal.pone.0128633.

• COMPLETE SITE INDEX

BotoxWiki provides evidence-focused educational content with transparent sourcing and editorial standards.

Clinical & Anatomy

Evidence & Review

Editorial & Trust

Reference Standard

BotoxWiki provides evidence-based content, medical review, and a neutral editorial approach to botulinum toxin formulations and anatomical guidance.

© BotoxWiki Clinical Reference Directory.